Finn Andrew L Form 4 March 18, 2008

FORM 4

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16. Form 4 or

January 31, Expires: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

2005 Estimated average burden hours per

0.5

Form 5 obligations

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

SECURITIES

response...

1(b).

(Print or Type Responses)

may continue.

See Instruction

1. Name and Address of Reporting Person * Finn Andrew L

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

BIODELIVERY SCIENCES INTERNATIONAL INC [BDSI]

(Check all applicable)

Vice President of Engineering

(Last)

(First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

03/14/2008

Director 10% Owner Other (specify X_ Officer (give title below) below)

C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE

SUITE 210

(Street)

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

X Form filed by One Reporting Person Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

RALEIGH, NC 27607

(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed Security (Month/Day/Year) Execution Date, if

any

(Month/Day/Year)

3. 4. Securities Acquired 5. Amount of Transaction(A) or Disposed of Code (D) (Instr. 8) (Instr. 3, 4 and 5)

6. Ownership 7. Nature of Form: Direct Indirect Securities Beneficially (D) or Beneficial Owned Indirect (I) Ownership Following (Instr. 4) (Instr. 4) Reported

(A) or Amount

Transaction(s) (Instr. 3 and 4) Price

802,413

Code (D)

Common Stock

(Instr. 3)

03/14/2008

 \mathbf{C} 5,000 2.05

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Finn Andrew L - Form 4

$\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (Instr. 3		Section Acquired (A) of Disput (D)	or posed of er. 3, 4,	6. Date Exerci Expiration Da (Month/Day/Y	te	7. Title and A Underlying S (Instr. 3 and	Securities
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)s	\$ 2.05	03/14/2008		С			5,000	(3)	07/27/2016	Common Stock	5,000
Stock Option (right to buy)s	\$ 6.63							<u>(1)</u>	04/13/2017	Common Stock	100,000
Stock Option (right to buy)s	\$ 2.85							(2)	01/31/2018	Common Stock	39,282
Stock Option (right to buy)s	\$ 2.94							<u>(4)</u>	07/28/2016	Common Stock	8,929
Stock Option (right to buy)s	\$ 3.4							10/21/2006	10/21/2016	Common Stock	5,147
Stock Option (right to buy)s	\$ 3.03							<u>(5)</u>	12/01/2015	Common Stock	49,000
Stock Option (right to buy)s	\$ 2.42							<u>(6)</u>	01/26/2017	Common Stock	37,209

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			

Reporting Owners 2

Finn Andrew L C/O BIODELIVERY SCIENCES INTERNATIONAL 801 CORPORATE CENTER DRIVE SUITE 210 RALEIGH, NC 27607

Vice President of Engineering

Signatures

/s/ Andrew Finn 03/17/2008

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) None of these stock options have vested and vesting of such options is subject to the continued employment of the reporting person.
- (2) None of these stock options have vested and vesting of such options is subject to the continued employment of the reporting person.
- (3) 5,201 of these stock options have vested and are exercisable, whereas the remainder of such options has not yet vested, subject to the continued employment of the reporting person.
- (4) 5,952 of these stock options have vested and are exercisable, whereas the remainder of such options has not yet vested, subject to the continued employment of the reporting person.
- (5) 32,666 of these stock options have vested and are exercisable, whereas the remainder of such options has not yet vested, subject to the continued employment of the reporting person.
- (6) 24,804 of these stock options have vested and are exercisable, whereas the remainder of such options has not yet vested, subject to the continued employment of the reporting person.
- (7) Not applicable. Board of Directors grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3